AKTX Quote, Financials, Valuation and Earnings

Ascendis Pharma AS has a net margin of -- compared to Akari Therapeutics PLC's net margin of -93.73%. Akari Therapeutics PLC's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 5825.93%. On the other hand Ascendis Pharma AS has an analysts' consensus of $221.46 which suggests that it could grow by 36%. Given that Akari Therapeutics PLC has higher upside potential than Ascendis Pharma AS, analysts believe Akari Therapeutics PLC is more attractive than Ascendis Pharma AS.

Akari Therapeutics PLC has a beta of 0.287, which suggesting that the stock is 71.306% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.314%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. Akari Therapeutics PLC's net income of -$3.7M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 24.25x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 5825.93%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1561.47%. Given that Akari Therapeutics PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Akari Therapeutics PLC is more attractive than Biodexa Pharmaceuticals PLC.

Akari Therapeutics PLC has a beta of 0.287, which suggesting that the stock is 71.306% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Akari Therapeutics PLC's net income of -$3.7M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 1.12x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of -170.14%. Akari Therapeutics PLC's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 5825.93%. On the other hand Cellectis SA has an analysts' consensus of $5.60 which suggests that it could grow by 283.56%. Given that Akari Therapeutics PLC has higher upside potential than Cellectis SA, analysts believe Akari Therapeutics PLC is more attractive than Cellectis SA.

Akari Therapeutics PLC has a beta of 0.287, which suggesting that the stock is 71.306% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.107, suggesting its more volatile than the S&P 500 by 210.711%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.7M. Akari Therapeutics PLC's net income of -$3.7M is higher than Cellectis SA's net income of -$18.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 2.99x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 5825.93%. On the other hand DBV Technologies SA has an analysts' consensus of $14.76 which suggests that it could grow by 76.75%. Given that Akari Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics PLC is more attractive than DBV Technologies SA.

Akari Therapeutics PLC has a beta of 0.287, which suggesting that the stock is 71.306% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Akari Therapeutics PLC's net income of -$3.7M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.